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Abstract
Background: There are no Italian data regarding the strategies for preventing neonatal group B streptococcal (GBS)
infection. We conducted a national survey in order to explore obstetrical, neonatal and microbiological practices for
the GBS prevention.
Methods: Three distinct questionnaires were sent to obstetricians, neonatologists and microbiologists.
Questionnaires included data on prenatal GBS screening, maternal risk factors, intrapartum antibiotic prophylaxis,
microbiological information concerning specimen processing and GBS antimicrobial susceptibility.
Results: All respondent obstetrical units used the culture-based screening approach to identify women who should
receive intrapartum antibiotic prophylaxis, and more than half of the microbiological laboratories (58%) reported
using specimen processing consistent with CDC guidelines. Most neonatal units (89 out of 107, 82%) reported
using protocols for preventing GBS early-onset sepsis consistent with CDC guidelines.
Conclusions: The screening-based strategy is largely prevalent in Italy, and most protocols for preventing GBS
early-onset sepsis are consistent with CDC guidelines. However, we found discrepancies in practices among centers
that may reflect the lack of Italian guidelines issued by public health organizations.
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Background
Preventive strategies reduce cases of group B streptococ-
cus early-onset sepsis. There are no previous Italian data
on strategies for preventing group B streptococcus early-
onset sepsis, although partial, area-based information
has been recently reported from 2 Italian regions.
This study provides an overview of Italian strategies
for preventing group B streptococcus early-onset sepsis
and evaluate the attitudes and practices of obstetrical
and neonatal units as well as microbiological laborator-
ies. It shows that a screening-based strategy is wide-
spread throughout the national territory despite the low
response rate. However, the discrepancies that have
emerged in practices among prenatal and neonatal pro-
viders as well as among laboratorians may reflect the
lack of national guidelines issued by public health orga-
nizations. Future interventions should rely on further
epidemiological data.
Introduction
Since 1970, Group B Streptococcus (GBS) has emerged
as the predominant cause of early-onset sepsis (EOS,
sepsis occurring within the first week of life [1]). Over
the past 10 years, due to the widespread of intrapartum
antibiotic prophylaxis (IAP), a significant reduction in
the incidence rates of the GBS-EOS has been achieved
[1]. Nevertheless, GBS remains a leading cause of neo-
natal morbidity and mortality in industrialized countries,
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and causes over one-third of cases of invasive EOS in
the US [1–5].
There is still controversy over how to identify women
who should receive IAP. Currently, there are two main ap-
proaches: under the culture-based approach, recom-
mended in US [5], IAP is offered to women with GBS
bacteriuria during the current pregnancy, or to women
who have previously delivered an infant with invasive GBS
disease or who are identified as GBS colonized at the
vaginal-rectal site in late pregnancy (35–37 weeks’ gesta-
tion). Under the risk-based approach (presence at the on-
set of labour of one of the following: previous infant with
invasive GBS disease, GBS bacteriuria during any semester
of current pregnancy, delivery at < 37 weeks’s gestation,
amniotic membrane rupture ≥ 18 h, intrapartum
temperature ≥ 38.0 °C), recommended in some European
countries, IAP is given to women with risk factors for
EOS [3]. However, a Centers for Disease Control and
Prevention (CDC) sponsored population-based, retro-
spective cohort study demonstrated that the screening-
based approach was at least 50% more effective than the
risk-based strategy [5]. After the release of the CDC guide-
lines in 1996, and their subsequent update in 2002 and
2010 [3, 4], the incidence of GBS-EOS has declined in the
US from 1.7 cases/1000 live births to 0.34–0.37 cases/
1000 live births [5]. The case fatality ratio has also
declined, over the past 25 years, from 25 to 50% to 4–6%
[5–7]. Furthermore, the meningeal invasion accompany-
ing GBS-EOS has reduced from 25% in the 1980s to the
current 4% of cases [6].
In 1996, the Italian Society of Perinatal Medicine
issued recommendations for the prevention of GBS-EOS
based on universal vaginal screening [8]. However, these
recommendations have not been updated since then. In
March 2012, in order to promote the knowledge and
endorse the use of the 2010 guidelines from CDC, the
Italian Society of Neonatology posted a translated
version in its website.
There are currently no data available regarding policies
for preventing GBS-EOS in Italian hospitals. Therefore,
we conducted a nationwide questionnaire survey in order
to describe the GBS-EOS preventive practices in mater-
nity and neonatal units and in microbiology laboratories.
Methods
In July 2012, questionnaires were sent to the heads of all
Italian maternity and neonatal units and the directors of
the microbiology laboratories, and to all members of the
Italian Society of Obstetricians and Gynecologists, the
Italian Society of Neonatology and the Italian Associ-
ation of Clinical Microbiologists. Three different ques-
tionnaires, approved by their respective scientific
societies, were sent to the head of each of the obstetric
and neonatal units, and microbiological laboratories
(online supplement). The questionnaires were sent in
electronic format, were accompanied by a cover letter
asking to report the policies in use to prevent GBS-EOS,
and feedback was sought with reminders.
Questionnaires were designed to gather information
about maternal, neonatal and microbiological aspects of
prevention of GBS-EOS and included demographic
information, data on maternal prenatal or intrapartum
GBS screening, data on IAP, risk factors for invasive
GBS-EOS (e.g. prolonged rupture of membranes, pre-
term delivery, maternal fever, GBS bacteriuria during
pregnancy, previous infant with GBS disease), hypothet-
ical scenarios for managing at risk babies and microbio-
logical data on specimen processing and resistant GBS
strains. The neonatal questionnaire also asked to report
retrospectively the number of live births from January
1st to December 31st, 2011, and the number of GBS
isolates from blood and/or cerebrospinal fluid (CSF) in
each unit.
Statistical analysis was performed using the Chi-
squared test and Mann–Whitney test for independent
samples, as appropriate. A p value <0.05 was considered
statistically significant.
Results
Responses from each professional category are pre-
sented, according to the respective geographical areas, in
Table 1 and Additional file 1: Table S1. Questionnaires
were returned from 34 out of 493 obstetrical units (7%),
from 107 out of 493 neonatal units (22%), and from 101
out of 338 microbiological laboratories (30%).
Obstetrical data
All respondent centers used the culture-based screening
approach to identify women who should receive IAP.
Nearly all respondents (88%) reported specimen collec-
tion for screening of GBS colonization both at the lower
vagina and ano-rectal sites. When asked about routine
timing for collection of samples, 91% of respondents re-
ported using collection at 35–37 weeks, according to the
CDC guidelines. No units reported using routinely bed-
side rapid molecular test for intrapartum screening of
pregnant women. Collection of urine cultures in asymp-
tomatic patients was extremely variable among units.
Most respondents administered ampicillin as their
first-line agent for IAP. Ampicillin was administered
every 4 h until delivery (24 units) or every 6 h (3 units)
or was not reported (7 units). For patients reporting a
history of allergy (without anaphylaxis) after exposure to
penicillin, the following antimicrobials were most com-
monly given: clindamycin (13 units), macrolides
(13 units) - including clarithromycin (4 units), erythro-
mycin (5 units), and azithromycin (2 units) - cefazolin/
cephalosporin (6 units), gentamycin (2 units) or
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vancomycin (1 unit). Of note, only 4 units (12%) re-
ported to test antimicrobial susceptibility for penicillin-
allergic women.
Neonatal data
Italian live births during 2011 were 554.428 (of which
261.083 in the North; 120.202 in the Centre; and
173.143 in the South of Italy). There were 171.390 live
births in respondent units during 2011, with wide differ-
ences in live births among centers. The total number of
blood and CSF cultures collected in neonates in each
centers, as well as indications for performing a lumbar
puncture is unavailable; however, positive blood cultures
were 86 and positive CSF cultures were 13. The inci-
dence rates of GBS sepsis and meningitis were therefore
0.50/1000 and 0.075 per 1000 live births, respectively.
Incidence rates of GBS sepsis were significantly lower in
Northern (0.36/1000 live births) compared to Central
(0.77/1000 live births, p = 0.017) and Southern Italy
(0.70/1000 live births, p = 0.003) (Table 2).
One hundred and six out of 107 neonatal units had
protocols for GBS-EOS prevention and 89 (82%) estab-
lished their policies based on the CDC guidelines. Pre-
ventive policies were adopted since 2000 in all units.
Previous infant with GBS sepsis, maternal GBS
colonization, GBS bacteriuria during the current preg-
nancy, prolonged membrane rupture ≥ 18 h, chorioam-
nionitis, intrapartum fever and prematurity (< 37 weeks)
were considered risk factors. Additional but less com-
mon (8%) risk factors included the following: young age
and African race of mother, persistent fetal tachycardia,
amniotic fluid stained with meconium or malodorous
meconium, neonatal colonization at mucous sites (aur-
icular and pharyngeal).
The management of neonates at risk for GBS EOS in
different clinical scenarios is summarized in Table 3.
In ninety-four units (88%), sepsis workup was not indi-
cated for asymptomatic full-term neonates born to a GBS
colonized mother exposed to adequate IAP (penicillin,
ampicillin or cefazolin administered more than 4 h prior
to delivery), and only observation for ≥ 48 h was recom-
mended. However, 81 (75.7%) respondents reported
laboratory evaluation and/or antimicrobial administration
for asymptomatic full-term neonates exposed to inad-
equate IAP (less than 4 h prior to delivery).
Approximately 40% of units reported blood testing (i.e.
white blood cell count, [WBC], blood culture, C reactive
protein) for asymptomatic preterm neonates exposed to
adequate IAP. Moreover, nearly all respondents (98;
91.5%) reported laboratory evaluation and/or antimicro-
bial treatment for preterm neonates born to mothers
carrying GBS exposed to inadequate IAP. Empirical anti-
microbial treatment was given to chorioamnionitis
exposed neonates (60% of cases) regardless of gestational
age or the duration of IAP; empirical antimicrobial treat-
ment was also given to preterm neonates exposed to
inadequate IAP (43% of cases).
Microbiological data
The stratification of data according to geographical dis-
tribution of respondents is reported in Table 4.
Sites of specimen collection for prenatal screening
were variable. In detail, 66.4% of specimens in Northern
Italy, 61.2% in Central Italy and 43.3% in Southern Italy
were collected from both lower vagina and rectum, as
recommended by CDC guidelines.
Ninety-per-cent of respondents reported using Stuart or
Amies transport medium for specimen transport, accord-
ing to CDC guidelines, and 58% followed CDC indications
for specimen processing (inoculation of specimen into
selective broth and then subculture of incubated broth to
an appropriate agar plate with or without initial step of
direct inoculation to agar plate). Even if the total of re-
spondents used appropriate agar plates for subculture of
incubated broth only 12% used selective broths recom-
mended by the CDC, e.g. Lim broth or Trans Vag broth.
Eighty-eight percent of respondents reported a 24–48 h
time interval for a positive response.
Table 1 Respondents divided by geographic area








North Italy 193 63 (32.64) 18 (9.3) 151 68 (45)
Central Italy 101 15 (14.8) 4 (3.9) 70 17 (24.3)
South Italy 199 29 (14.6) 12 (6) 117 16 (13.7)
TOTAL 493 107 (21.7) 34 (6.9) 338 101 (29.8)
Table 2 Incidence of positive blood and CSF culture stratified
by geographic area
North Italy Central Italy South Italy
LBa per respondent units 108.725 30.352 32.313
Positive blood cultures (n) 40 21 25
Incidence per 1000 LBa 0.36 0.77 0.70
Positive CSF cultures (n) 5 6 2
Incidence per 1000 LBa 0.045 0.22 0.056
aLB live births
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When asked about antibiotic susceptibility of GBS iso-
lates, 4 centers did not performed susceptibility tests
and 37 centers (36.6% of respondents) did not provide
any information. Of the 60 centers where susceptibility
testing was performed, 2 centers did not provide any re-
sistance rates and in the remaining 58 centers resistance
rates varied widely from less to 10 to more than 50% of
strains with the majority of macrolide and clindamycin
resistance reported to be between 10 and 30% of strain
(33 and 29% of isolates were reported resistant to
macrolide and clindamycin respectively).
Discussion
We report here the results of the first nationwide sur-
vey aiming to describe the preventive practices for
GBS-EOS in Italy both from the clinical and the micro-
biological perspectives.
Area-based information has been recently reported
from two Italian regions [9–11], but no nationwide data
on GBS prevention practices has been previously pub-
lished. Although partial and not area-based, the informa-
tion obtained through the current study is a preliminary
step for planning future interventions.
Obsteric and microbiologic practices
Almost all respondent units reported using a screening-
based approach with culture collection at 35–37 weeks’
gestation. The culture-based strategy is recommended in
the United States and in some European countries includ-
ing Spain, Germany, Italy and France. The risk-based
strategy is adopted in the United Kingdom, the
Netherlands, Norway, and Denmark [12, 13] and reflects
the view that the incidence of GBS-EOS will not reduce
any further with the introduction of universal screening
for GBS in pregnancy. No units routinely used bedside
rapid molecular tests for intrapartum screening of preg-
nant women. Most units reported collecting vagino-rectal
specimens (as recommended by CDC guidelines) [5].
However, only 58% of microbiological laboratories re-
ported specimen processing consistent with CDC guide-
lines [5]. Furthermore, most units reported administering
ampicillin (instead of penicillin) as their first line agent for
IAP. Penicillin is recommended in the US guidelines [4, 5]
because of its narrow spectrum, but, unfortunately, it is
not produced in Italy. In case of allergic mothers without
anaphylaxis, most units, reported administering clindamy-
cin or, different from CDC guidelines, macrolides. Only
few units reported using cefazolin (the agent recom-
mended by CDC guidelines for pregnant women with low
risks of anaphylaxis), or reported testing of antimicrobial
susceptibility for allergic women. Increasing resistance of
GBS to macrolides and clindamycin is a major concern
worldwide, and the use of clindamycin is specifically dis-
couraged by the CDC guidelines, unless the pregnant
woman is at high risk of anaphylaxis and susceptibility test
has been performed [5]. Furthermore, erythromycin is no
longer recommended. Although most units reported ad-
ministering antimicrobials every 4 h, some gave intrapar-
tum antimicrobials every 6 h, a practice not provided by
consensus guidelines.
Neonatal practices
Despite the absence of national guidelines, all respond-
ent units reported to have protocols to prevent GBS-
EOS, in most cases consistent with CDC recommenda-
tions [5]. Although there was overall consensus for the
majority of risk factors (the same as suggested by CDC
guidelines) [5], some differences among centers were ap-
parent. Some units reported collecting swabs at neonatal
mucous sites (ear and throat). Based on CDC guidelines
Table 3 Strategies for managing asymptomatic babies at risk for EOS
Scenarios Observation ≥ 48 h Observation ≥ 48 h
+ laboratory evaluation




± IAP, n a
5 (5%) 38 (35%) 64 (60%)
Term neonate
Adequate IAP, n 94 (88%) 12 (11%) 1 (1%)
Inadequate IAP, n 26 (24%) 49 (46%) 32 (30%)
Preterm neonate
Adequate IAP, n 61 (57%) 44 (41%) 2 (2%)
Inadequate IAP, n 9 (8.5%) 52 (48.5%) 46 (43%)
aIAP intrapartum antibiotic prophylaxis, n = number (and percentage) of centers with a given strategies
Table 4 Distribution of swabs during a 3 years period divided
by geographic area
North Italy Central Italy South Italy
Vaginal swabs 36.295 9.673 9.883
Vaginal-rectal swabs 71.646 15.234 7.559
Total 107.941 24.907 17.442
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and the available literature, this practice should be dis-
couraged, as most colonized neonates remain healthy.
Most units reported not obtaining a sepsis workup for
asymptomatic full-term neonates born to a GBS colo-
nized mother exposed to adequate IAP. However, only
~25% of units reported observing asymptomatic neo-
nates (without further testing or antimicrobial treat-
ments) after exposure to inadequate IAP (as suggested
by CDC guidelines) [5, 14, 15]. Indeed, approximately
half of the units reported obtaining sepsis workup in
full-term neonates and 30% reported administering em-
pirical antimicrobial treatments; 43% reported anti-
microbial treatment in preterm neonates, practices not
consistent with CDC algorithms. Of note, only 60% of
respondents would treat babies whose mothers had
chorioamnionitis (as suggested by CDC guidelines). Al-
gorithms for the management of neonates at risk for
GBS-EOS, incorporated into the CDC and AAP guide-
lines have been repeatedly updated in recent years [5,
14, 15]. However, laboratory tests add little diagnostic
information because of poor specificity and low positive
predictive value, and their utility for a timely diagnosis
of EOS in asymptomatic, high-risk neonates, has been
questioned [15–19]. In order to reduce unnecessary
evaluations and antimicrobial therapies, some recent
guidelines currently recommend observation without
further testing or treatments for asymptomatic full-term
neonates born to a GBS colonized mother exposed to in-
adequate IAP [5, 15, 20, 21]. The lack of clinical evi-
dence and uncertainty regarding the management of at
risk neonates (mostly those who are asymptomatic), and
the absence of national expert consensus guidelines have
led in the current study to approaches which rely on
local protocols or on the choice of individual clinicians.
This can explain the differences between data here re-
ported and CDC guidelines.
Although we have no information on the total number
of blood and CSF cultures collected in neonates, in the
current study rates of positive blood cultures were sig-
nificantly higher in Central compared to Northern and
Southern Italy. Furthermore, incidence rates of GBS-
EOS in all geographical areas were higher than rates
found in two recent prospective Italian area-based stud-
ies (0.10/1000 live births in Friuli Venezia Giulia, and
0.19/1000 live births in Emilia-Romagna.) [9, 10, 22].
This discrepancy may be due to the retrospective nature
of the current study, as well as to inaccurate reporting;
indeed, this study was not specifically designed to deter-
mine the incidence of EOS and no strict criteria for
diagnosing infections were required.
Our study has some limitations. First, due to the low
rate of feedback from clinicians and microbiological units,
a selection bias may have occurred. Consequently, our
data may only partially reflect the nationwide policies.
Second, the study was conducted in 2012. This aspect is
particularly important for microbiological tests, that may
have been updated with newer available technologies since
then. Finally, the estimate of positive blood and CSF cul-
tures may have been biased and further, prospective, more
accurate data are required to address this question. Never-
theless, this survey would be useful to give a cross-section
of current practices for preventing GBS-EOS and prompt
the publication of national guidelines.
Conclusions
Our data show that the screening-based strategy is largely
prevalent and, despite shortcomings and variation among
centers, most protocols for preventing GBS EOS are con-
sistent with CDC guidelines. Discrepancies in practices
among prenatal and pediatric providers, and laboratorians
may reflect the lack of guidance issued by public health
organizations. The findings of our survey warrant the
issue of new Italian consensus guidelines. Furthermore, in
order to track the incidence of GBS-EOS and the impact
of perinatal prevention interventions regionals data and
laboratory-based surveillance systems are required.
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